  Boston Analytics (Boston, MA) has released a report examining economic opportunities in the pharmaceutical market in India. Titled, “An  Introduction to the Indian Pharmaceutical Industry,” the report examines the  elements that will lead to a 13.5 percent compound annual growth rate (CAGR) in  domestic production and sales of active pharmaceutical ingredients (API) and  generic drugs by 2010 as well as the booming Indian pharmaceutical outsourcing  market that is expected to see a 37.5 percent CAGR in that same time span. 

The report features a section detailing the factors leading to the  internal demand for drugs, including the country’s increasing population, an  ever-expanding consumer base in the middle and upper income brackets, the need  for improved healthcare infrastructure, and Indian companies’  reverse-engineering skills. Boston Analytics forecasts the domestic  pharmaceutical market will reach $10.3 billion by 2010. 

The report then examines the Indian outsourcing market in the  context of the global pharmaceutical landscape, delving into sub-categories of  growth including contract research, contract manufacturing, and other services.  India has 75 FDA approved pharmaceutical plants-the most of any country outside  the United States. The report estimates India’s pharmaceutical outsourcing  market will hit $3.3 billion in the next two years. 

An Introduction to the Indian Pharmaceutical Industry

” can be  found at the Boston Analytics website. 

News

Boston Analytics (Boston, MA) has released a report examining economic opportunities in the pharmaceutical market in India.